Greenwich Lifesciences Inc (GLSI) has a current Price-to-Book (P/B) ratio of 122.92. Compared to its 3-year average P/B ratio of 39.85, the current P/B ratio is approximately 208.43% higher. Relative to its 5-year average P/B ratio of 28.44, the current P/B ratio is about 332.19% higher. Greenwich Lifesciences Inc (GLSI) has a Forward Free Cash Flow (FCF) yield of approximately -3.18%. Compared to its 3-year average FCF yield of -4.73%, the current FCF yield is approximately -32.65% lower. Relative to its 5-year average FCF yield of -3.72%, the current FCF yield is about -14.49% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GLSI competitors is 7.51, providing a benchmark for relative valuation. Greenwich Lifesciences Inc Corp (GLSI.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GLSI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GLSI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GLSI currently overvalued or undervalued?

What is Greenwich Lifesciences Inc (GLSI) fair value?

GLSI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Greenwich Lifesciences Inc (GLSI) is between to according to relative valuation method.

How does GLSI's valuation metrics compare to the industry average?

The average P/S ratio for GLSI's competitors is 7.51, providing a benchmark for relative valuation. Greenwich Lifesciences Inc Corp (GLSI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Greenwich Lifesciences Inc (GLSI) as of Mar 03 2026?

As of Mar 03 2026, Greenwich Lifesciences Inc (GLSI) has a P/B ratio of 122.92. This indicates that the market values GLSI at 122.92 times its book value.

What is the current FCF Yield for Greenwich Lifesciences Inc (GLSI) as of Mar 03 2026?

As of Mar 03 2026, Greenwich Lifesciences Inc (GLSI) has a FCF Yield of -3.18%. This means that for every dollar of Greenwich Lifesciences Inc's market capitalization, the company generates -3.18 cents in free cash flow.

What is the current Forward P/E ratio for Greenwich Lifesciences Inc (GLSI) as of Mar 03 2026?

As of Mar 03 2026, Greenwich Lifesciences Inc (GLSI) has a Forward P/E ratio of -14.69. This means the market is willing to pay $-14.69 for every dollar of Greenwich Lifesciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Greenwich Lifesciences Inc (GLSI) as of Mar 03 2026?

As of Mar 03 2026, Greenwich Lifesciences Inc (GLSI) has a Forward P/S ratio of 0.00. This means the market is valuing GLSI at $0.00 for every dollar of expected revenue over the next 12 months.

GLSI Valuation